Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues

References

• World Health Organization. Global Hepatitis Report; 2017 Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 72, 2020.
   Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Chinese Medical Association. The Guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan ZangBing Za Zhi. 2011;19:13–24.
   PubMedGoogle Scholar
• Liu Y, Wang C, Zhong Y, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat. 2011;18(4):e29–39. doi:10.1111/j.1365-2893.2010.01360.x21392168
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593–1608. doi:10.1053/j.gastro.2009.08.06319737565
   PubMed Web of Science ®Google Scholar
• Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance variants in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res. 2010;85(3):512–519. doi:10.1016/j.antiviral.2009.12.00620034521
   PubMed Web of Science ®Google Scholar
• Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009;24(8):1417–1423. doi:10.1111/j.1440-1746.2009.05864.x19486254
   PubMed Web of Science ®Google Scholar
• Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):23–27. doi:10.1111/j.1365-2893.2009.01149.x19566788
   PubMed Web of Science ®Google Scholar
• Mirandola S, Campagnolo D, Bortoletto G, et al. Large-scale survey of naturally occurring HBV polymerase variants associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18(7):e212–216. doi:10.1111/j.1365-2893.2011.01435.x21692935
   PubMed Web of Science ®Google Scholar
• Salpini R, Svicher V, Cento V, et al. Characterization of drug-resistance variants in HBV D-genotype chronically infected patients, naïve to antiviral drugs. Antiviral Res. 2011;92(2):382–385. doi:10.1016/j.antiviral.2011.08.01321920388
   PubMed Web of Science ®Google Scholar
• Vutien P, Trinh HN, Garcia RT, et al. Variants in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12(8):1363–1370. doi:10.1016/j.cgh.2013.11.03624342744
   PubMed Web of Science ®Google Scholar
• Li X, Liu Y, Zhao P, et al. Investigation into drug-resistant variants of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection. Antivir Ther. 2015;20(2):141–147. doi:10.3851/IMP281324992206
   PubMed Web of Science ®Google Scholar
• Gomes-Gouvêa MS, Ferreira AC, Teixeira R. HBV carrying drug-resistance variants in chronically infected treatment-naive patients. Antivir Ther. 2015;20(4):387–395. doi:10.3851/IMP293825624410
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu J, Sun L, et al. Prevalence of variants in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016;20(2):173–178. doi:10.1016/j.bjid.2015.12.00626876337
   PubMed Web of Science ®Google Scholar
• Xu J, Wu B, Wang JH, et al. Pre-existing variants in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B. PLoS One. 2015;10(3):e0117429. doi:10.1371/journal.pone.011742925821965
   PubMed Web of Science ®Google Scholar
• Fu Y, Zeng Y, Chen T, et al. Characterization and clinical significance of natural variability in Hepatitis B virus reverse transcriptase in treatment-naive chinese patients by Sanger sequencing and next-generation sequencing. J Clin Microbiol. 2019;57(8):e00119–e00219. doi:10.1128/JCM.00119-1931189581
   PubMed Web of Science ®Google Scholar
• Qian F, Qin J, Li D, et al. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China. J Infect Dev Ctries. 2016;10(9):996–1002. doi:10.3855/jidc.802027694733
   PubMed Web of Science ®Google Scholar
• Fan J, Zhang Y, Xiong H, et al. Nucleotide analogue-resistant variants in hepatitis B viral genomes found in hepatitis B patients. J Gen Virol. 2015;96(Pt 3):663–670. doi:10.1099/jgv.0.00001025481755
   PubMed Web of Science ®Google Scholar
• Pacheco SR, Dos Santos MIMA, Stocker A, et al. Genotyping of HBV and tracking of resistance variants in treatment-naïve patients with chronic hepatitis B. Infect Drug Resist. 2017;5(10):201–207. doi:10.2147/IDR.S135420
   Web of Science ®Google Scholar
• Zhang Q, Liao Y, Cai B, et al. Incidence of natural resistance variants in naïve chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30(2):252–261. doi:10.1111/jgh.1283125318660
   PubMed Web of Science ®Google Scholar
• Liu, Zhou Y, Li X, et al. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. Emerg Microbes Infect. 2019;8(1):354–365. doi:10.1080/22221751.2019.158401830866789
   PubMed Web of Science ®Google Scholar
• Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70(6):1093–1102. doi:10.1016/j.jhep.2019.02.00630794889
   PubMed Web of Science ®Google Scholar
• Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus variants in the polymerase region. Hepatology. 2001;33(3):751–757. doi:10.1053/jhep.2001.2216611230757
   PubMed Web of Science ®Google Scholar
• Li H, Song XF, Hu TT, et al. A strong conservative tendency in HBV transcriptase (RT): a majority of natural RT variants derived from the S gene. Liver Int. 2016;36(7):963–970. doi:10.1111/liv.1305126707356
   PubMed Web of Science ®Google Scholar
• Yamani LN, Yano Y, Utsumi T, et al. Profile of variants in the reverse transcriptase and overlapping surface genes of Hepatitis B Virus (HBV) in treatment-Naïve Indonesian HBV carriers. Jpn J Infect Dis. 2017;70(6):647–655. doi:10.7883/yoken.JJID.2017.07829093313
   PubMed Web of Science ®Google Scholar
• Zheng J, Zeng Z, Zhang D, et al. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32(10):1535–1542. doi:10.1111/j.1478-3231.2012.02859.x22882650
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee SY, Kim H, et al. Naturally occurring variants in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2. World J Gastroenterol. 2017;23(23):4222–4232. doi:10.3748/wjg.v23.i23.422228694662
   PubMed Web of Science ®Google Scholar
• Su M, Xiang K, Li Y, et al. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2. Infect Genet Evol. 2016;40:275–281. doi:10.1016/j.meegid.2016.03.01927006281
   PubMed Web of Science ®Google Scholar
• Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase variants related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol. 2018;24(16):28. doi:10.3748/wjg.v24.i16.1708
   Web of Science ®Google Scholar
• Zhu B, Wang T, Wei X, et al. Accumulation of variants in reverse transcriptase of hepatitis B virus is associated with liver disease severity in treatment-naïve Chinese patients with chronic hepatitis B. Adv Clin Exp Med. 2017;26(7):1123–1129. doi:10.17219/acem/6399829211361
   PubMed Web of Science ®Google Scholar
• Nishijima N, Marusawa H, Ueda Y, et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One. 2012;7(4):e35052. doi:10.1371/journal.pone.003505222523569
   PubMed Web of Science ®Google Scholar
• Ciftci S, Keskin F, Cakiris A, et al. Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method. Diagn Microbiol Infect Dis. 2014;79(1):25–30. doi:10.1016/j.diagmicrobio.2014.01.00524630522
   PubMed Web of Science ®Google Scholar
• Zhang X, Li M, Xi H, et al. Pre-existing variants related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing. Oncotarget. 2016;7(43):70264–70275. doi:10.18632/oncotarget.1184027602500
   PubMedGoogle Scholar
• Ko SY, Oh HB, Park CW, et al. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect. 2012;18(10):E404–411. doi:10.1111/j.1469-0691.2012.03951.x22757653
   PubMed Web of Science ®Google Scholar
• Widasari DI, Yano Y, Heriyanto DS, et al. A deep-sequencing method detects drug-resistant variants in the hepatitis B virus in Indonesians. Intervirology. 2014;57(6):384–392. doi:10.1159/00036642025382636
   PubMed Web of Science ®Google Scholar
• Jones LR, Sede M, Manrique JM, et al. Hepatitis B virus resistance substitutions: long-term analysis by next-generation sequencing. Arch Virol. 2016;161(10):2885–2891. doi:10.1007/s00705-016-2959-827447462
   PubMed Web of Science ®Google Scholar
• Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199(9):1275–1285. doi:10.1086/59780819301976
   PubMed Web of Science ®Google Scholar